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Abstract Zinc and zirconium were selected as the
alloying elements in biodegradable magnesium alloys,
considering their strengthening effect and good biocom-
patibility. The degradation rate, hydrogen evolution, ion
release, surface layer and in vitro cytotoxicity of two
Mg–Zn–Zr alloys, i.e. ZK30 and ZK60, and a WE-type
alloy (Mg–Y–RE–Zr) were investigated by means of long-
term static immersion testing in Hank’s solution, non-static
immersion testing in Hank’s solution and cell-material
interaction analysis. It was found that, among these three
magnesium alloys, ZK30 had the lowest degradation rate
and the least hydrogen evolution. A magnesium calcium
phosphate layer was formed on the surface of ZK30 sample
during non-static immersion and its degradation caused
minute changes in the ion concentrations and pH value of
Hank’s solution. In addition, the ZK30 alloy showed
insigniﬁcant cytotoxicity against bone marrow stromal
cells as compared with biocompatible hydroxyapatite (HA)
and the WE-type alloy. After prolonged incubation for
7 days, a stimulatory effect on cell proliferation was
observed. The results of the present study suggested that
ZK30 could be a promising material for biodegradable
orthopedic implants and worth further investigation to
evaluate its in vitro and in vivo degradation behavior.
1 Introduction
In recent years, there has been growing interest in magne-
sium alloys as a new generation of biodegradable materials
[1]. Biodegradable magnesium and its alloys are advanta-
geous over existing biodegradable materials such as poly-
mers, ceramics and bioactive glasses in load-bearing
applications where sufﬁcient strength and Young’s modulus
close to that of the bone are required [2]. However, fast
degradation of magnesium due to corrosion in the human
bio-environmentmaylimititsclinicalapplications[1,3],for
example, orthopedic applications, because a too high degra-
dation rate leads to premature deterioration ofbiofunctionality.
Alloying is a general approach to improving the corro-
sion resistance of magnesium as well as its mechanical
properties. It is however restricted in the case of designing
magnesium alloys for biomedical applications, when the
toxicity of alloying elements is taken into consideration.
Most of the magnesium alloys that have so far been
investigated as potential implant materials are rather
complex in alloy composition and contain potentially toxic
alloying elements [1, 4]. Aluminum-containing magnesium
alloys, for example, are not preferred material choices for
biomedical applications, because accumulation of alumi-
num is associated with various neurological disorders [5].
As to the alloys containing rare earth mischmetal elements
in addition to yttrium (e.g. WE43), controversy exists as to
the biological effects of rare-earth elements in these alloys
[6, 7]. In a clinical trial for acute treatment of a newborn
with severely impaired heart function, for example,
Mg-based absorbable stents containing rare-earth elements
are reportedly not tolerated [8].
In principle, in the design and selection of a biode-
gradable metallic material, elements with potential toxi-
cological problems should be avoided altogether or limited
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really be excluded from the alloy [9]. Another important
issue, which is sometimes not addressed, concerns the
composition and processing of the material. Both should
not be too complex to make systematic in vivo evaluation
as well as further alloy and processing optimization difﬁ-
cult. With the above considerations in mind, in the present
research, zinc and zirconium were chosen as the alloying
elements in biodegradable magnesium alloys for biomedi-
cal applications. Zinc (Zn) is a common alloying ingredient
in magnesium and its strengthening effect is second only to
aluminum. It helps overcome the harmful corrosive effect
of impurities such as iron and nickel, thus improving the
corrosion resistance of magnesium alloys [10, 11]. Its
concentration is usually limited to 3% for good corrosion
resistance [12, 13]. In addition, zinc is considered an
essential micro-nutrient, as zinc-deﬁciency may result in
strongly perturbed physiological functions in the human
body [14]. Zirconium (Zr) is usually used as a grain reﬁner
in magnesium alloys without aluminum, thereby contrib-
uting to the strength of these alloys [15]. It also reduces the
adverse effect of iron contaminant on the corrosion resis-
tance of magnesium alloys [16]. In the Mg–Zr binary alloy
system, zirconium is effective in enhancing corrosion
resistance only when its content is less than 0.48% with no
Zr-containing precipitates forming [17]. While the impor-
tance of zirconium in the human body is still being deter-
mined, it has been reported that zirconium shows both in
vitro and in vivo good biocompatibility and osseointegra-
tion, even outperforming titanium [18, 19].
Up till now, limited research has been carried out on
Mg–Zn–Zr alloys as potential biodegradable materials,
although an addition of zinc to magnesium was recognized
as a good direction to take [3]. Notwithstanding this, it has
been conﬁrmed that the Mg–6Zn–0.6Zr alloy (ZK60) in
simulated body ﬂuid degrades faster than pure magnesium
[13]. Therefore, a leaner magnesium alloy with 3% Zn and
0.6% Zr (ZK30) was selected for the present research. To
authors’ best knowledge, no preceding research had been
carried out on this alloy for biomedical applications. As
can be seen from Table 1, with the same Zr content, ZK30
mechanically underperforms ZK60 only to a limited extent.
In the present study, in vitro degradability of ZK30 was
evaluated with respect to mass loss and hydrogen evolution
during long-term static immersion tests. Its degradation
behavior was further investigated in terms of ion release and
pH value of non-static Hank’s solution over a period of
7 days. Its cytocompatibility was evaluated by testing cell
viability in vitro under the inﬂuence of the eluate of the
material[7,20].ComparisonwasmadewithaWE-typealloy
as well as with hydroxyapatite (HA) in order to establish the
viability of the ZK30 alloy as a potential biodegradable
material for biomedical applications. The rationale behind
choosing a WE-type alloy for comparison purposes was that
the WE43 alloy was previously investigated in vitro and in
vivoasapotentialmaterialfororthopedicapplicationsandit
showed good corrosion resistance and cytocompatibility,
relative to other magnesium alloys (AZ31, AZ91 and
LAE42) [6].Itstypicaltensilepropertiesincomparisonwith
those of ZK30 and ZK60 are given in Table 1.
2 Materials and experimental details
2.1 Material preparation
ZK60 and ZK30 alloys were prepared from high-purity Mg
([99.95%), Zn ([99.9%) and Mg–30Zr (wt%) master
alloy. A WE-type alloy was prepared from high purity-Mg
([99.95), pure yttrium, pure neodymium and gadolinium
(Nd:Gd = 80:20, instead of Nd-rich rare earths), as well as
Mg–30Zr master alloy. The raw materials were melted in
an electric-resistance furnace under gas ﬂux protection.
After a grain-reﬁning procedure at 760–800C, the melt
was poured into a steel mould preheated to 200–300C.
After solidiﬁcation, rods were cut from the ingots and a
surface layer was machined off. The rods were cut into
disks with a diameter of 28 mm and a thickness of 5 mm
without further polishing. The exact chemical compositions
of the ZK30, ZK60 and WE-type alloy disks determined
using an X-ray ﬂuorescence spectrometer (Phillips PW-
4200) are given in Table 2.
2.2 Static immersion tests to determine degradation
rate and hydrogen evolution
While the conventional corrosion testing techniques, such
as potentiometric testing, are of great value for the
Table 1 Typical mechanical properties of the ZK30, ZK60 and WE43 alloys [2]
Alloy Nominal composition 0.2% proof
strength (MPa)
Ultimate tensile
strength (MPa)
Elongation at
fracture (%)
ZK30 Mg–3Zn–0.6Zr 215 300 9
ZK60 Mg–6Zn–0.6Zr 235 315 8
WE-43 Mg–4Y–3RE
a–0.5Zr 160 260 6
a RE consists of 2.0–2.5% neodymium, the remainder being heavy rare earths, principally ytterbium, erbium, dysprosium and gadolinium
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123assessment of the potential of an alloy to corrode, they do
not provide information speciﬁc to the possibility of the
alloy to be considered as a degradable biomaterial [21].
Therefore, instead of electrochemical testing, long-term
static immersion tests in Hank’s solution, together with the
measurement of hydrogen evolution [13], were performed
to investigate the degradation behavior of the alloys over a
period of 21 weeks. A burette ﬁlled with the solution was
placed over the sample in a beaker ﬁlled with the same
solution in order to collect the hydrogen evolving during
the degradation tests. The tests were performed at 37.0C
in a thermostatic bath. Hank’s solution was selected,
because it represented the ion concentrations of blood
plasma [22]. The ion concentrations of Hank’s solution in
comparison with those of human blood are presented in
Table 3 [23]. As can be seen, the Cl
- ion concentration in
Hank’s solution is actually higher than that in human
blood, thus presenting a highly hostile condition for mag-
nesium alloys. For each disk-shaped sample, 250 ml of
Hank’s solution was used. During the testing over
21 weeks, the whole immersion system was regularly re-
ﬁlled with deionized water to a level of 250 ml in order to
compensate for the liquid loss due to evaporation in the
ambient atmosphere. Mass loss was registered once a week
and the hydrogen evolution was monitored on a daily basis.
2.3 Non-static immersion tests to analyze ion release
and characterize surface layer
To investigate the behavior of ion release in greater detail
and characterize the surface layer at the early stage of
degradation, samples in the form of disks with a diameter
of 10 mm, a thickness of 2 mm and thus a surface-area-to-
volume ratio of 0.1 cm
-1 were prepared and immersed in
Hank’s solution at 37.0C[ 24]. A shaker incubator was
used and agitation was maintained at 30 rpm. To determine
the inﬂuence of a compositional change of Hank’s solution
on the in vitro behavior of the alloys, after 24 h immersion,
one half of the volume of the soaking medium was col-
lected for further investigation and the rest refreshed with
new Hank’s solution. An inductively coupled plasma
optical emission spectrometer (ICP-OES, PerkinElmer
Optima 3000dv) was employed to determine the concen-
trations of magnesium and other metal ions dissolved from
the disk samples. The changes in Ca and P ions were also
registered. The pH value of the solution collected after
24 h immersion was measured using an electrolyte-type pH
meter (pH-meter CG840, Den Bosch, Holland). The pro-
cedure was repeated every day throughout a period of
7 days. The initial ion concentrations and pH value of
Hank’s solution were taken as the starting points and used
as the data of day zero.
After 1-day and 7-day non-static immersion as described
above, samples were taken out of the soaking medium and
gently rinsed with deionized water to remove retained
soaking medium. Their surfaces were cleaned with ethanol,
followed by drying at room temperature. To identify the
compounds of the surface layer, an X-ray diffractometer
(XRD, Bruker-AXS D5005) was used with 2-theta angles
ranging from 10 to 80. Diffraction spectra were inter-
preted qualitatively using the powder diffraction ﬁle (PDF).
The surface morphology and the compositions of the
compounds formed on the sample surfaces after non-static
immersion were analyzed by using a scanning electron
microscope (JSM-6500F, JEOL) equipped with an energy
dispersive X-ray (EDX) spectrometer (INCA Energy,
Oxford Instruments).
2.4 Cytotoxicity testing of degradation products
Rabbit bone marrow stromal cells (rBMSC) were isolated
and expanded using an established method with minimum
modiﬁcations [25]. Cytotoxicity tests were carried out by
indirect contact. The cells were cultured in the extracts
from the degrading material. Extracts were prepared using
a RPMI 1640 (Gibco) cell culture medium as the extraction
medium with an extracting medium volume to surface area
ratio of 1.25 ml/cm
2 in a humidiﬁed atmosphere with 5%
Table 2 Chemical compositions of the magnesium alloys under
investigation (wt%)
Alloys Zn Zr Fe Cu Ni Y RE
a Mg
ZK30 3.15 0.43 0.007 –
b – – – Bal.
ZK60 5.86 0.42 – – – – – Bal.
WE-type 0.006 0.42 0.011 – – 5.00 3.61 Bal.
a RE consists of Nd and Gd at a ratio of Nd:Gd = 80:20
b Indicates that the concentration is lower than 50 mg/kg
Table 3 Ion concentrations in human blood and Hank’s solution (mg/L)
Na
? K
? Ca
2? Mg
2? Cl
- HCO3
- HPO4
2- and H2PO4
-
Blood plasma [23] 3266 156 100 24 3657 1708 246
Hank’s solution
a 3241 226 46 17 5135 254 75
a Data posted on the website www.sigmaaldrich.com and the elemental concentrations of Ca, Mg and P, measured by using ICP-OES, being
45.8, 16.9 and 21.8 mg/l, respectively
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123CO2 at 37C for 24 h [7]. The supernatant ﬂuid was
withdrawn and centrifuged to prepare the extraction culture
medium.
Cell suspension was adjusted to a density of 1 9 10
4
cell/ml and 100 ll of cell suspension was added to each
well of a 96-well plate and incubated for 24 h. The culture
medium was then removed and replaced by 50 llo f
extracts and 50 ll of RPMI 1640 medium supplemented
with 20% fetal calf serum (FCS) every second day. The
number of viable cells was quantitatively assessed by the
MTT test [26]. MTT (Sigma) [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide] is a yellow tetra-
zolium salt that can be enzymatically converted by a living
cell to a purple formazan product. The intensity of the color
produced is therefore directly proportional to the number of
viable cells in culture and thus to their proliferation in
vitro. The absorbance of the color can be measured at
590 nm (A590). In the present tests, after incubating at
37C and in an atmosphere with 5% CO2 for one and
7 days [7, 27], 100 ll of the 0.5 mg/ml MTT solution was
added to the well plate and incubated for 4 h at 37C. Then
100 ll of dimethyl sulfoxide was added to each well and
the plate was shaken for 5 min. The optical density (OD) at
590 nm was measured with an enzyme-linked immunoad-
sorbent assay plate reader (ELX800, Bio-TEK). A cyto-
compatible hydroxyapatite (HA) disk was used as reference
[28, 29]. Six samples per group were tested in the experi-
ment. The results were compared in OD units.
2.5 Statistical methods
The experimental values were analyzed using the Student’s
t-test and expressed by the mean values ± standard devi-
ation (SD). A P-value\0.05 was considered statistically
signiﬁcant.
3 Results
3.1 Mass loss and hydrogen evolution during static
immersion
The mass loss of samples during the static immersion tests
is shown in Fig. 1. It can be seen that ZK30 and WE-type
alloy samples had quite similar degradation rates during the
ﬁrst 14 weeks of immersion. However, during prolonged
immersion from 14 to 21 weeks, the degradation rate of
WE-type alloy sample deviated slightly from that of ZK30
sample. It is remarkable that the mass loss of the ZK30
sample in the immersion tests for 21 weeks was still
minute, while ZK60 showed an accelerated degradation
rate in the ﬁrst 9 weeks. At the end of week 12, ZK60
sample was completely degraded.
Surface macro-morphologies of some of the samples
throughout 21-week static immersion tests are shown in
Fig. 2. These reveal distinct degradation modes of the
alloys investigated. For the WE-type alloy (Fig. 2a, b),
localized pitting was the main mode of degradation at the
early stage of the static immersion tests. With testing time
passing on, discrete spots on the surface developed further,
resulting in a slightly porous surface morphology (Fig. 2b).
Toward week 21, an increasing number of drop-off parti-
cles were detached from the sample bulk (Fig. 2c). The
ZK60 alloy showed a degradation mode similar to the
WE-type alloy, but the degradation rate was signiﬁcantly
higher. Selective attack of the immersion solution on the
magnesium matrix led to rapid material dissolution, thus
resulting in an increased degradation rate and a highly
porous surface morphology (Fig. 2d). Further chemical
attack led to the disintegration of the sample (Fig. 2e).
However, the ZK30 alloy showed a completely different
mode of degradation. Throughout the immersion testing
period of 21 weeks, shallow pitting damage was uniform
on the sample surface (Fig. 2h). Pits developed very slowly
with time (Fig. 2f, g). Few drop-off particles detached from
the sample bulk were found in the immersion solution after
21 weeks, indicating that the material was able to retain its
shape and structural integrity for at least 5 months.
Figure 3 compares the samples in hydrogen evolution
during the static immersion tests. As can be seen, ZK60
showed quick and strong hydrogen evolution, correspond-
ing to its degradation behavior, as shown in Fig. 1. For the
WE-type alloy, however, at the early stage of immersion
testing, the hydrogen evolution rate was very low and
started to rise slightly after 16 weeks (112 days). Com-
pared with ZK60 and the WE-type alloy, ZK30 showed
markedly different behavior; hydrogen evolution remained
Fig. 1 Mass loss as a function of time during static immersion in
Hank’s solution
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21 weeks.
3.2 Microstructure and composition of the surface
layer formed during non-static immersion
Figure 4 shows the surface morphologies of ZK30, ZK60
and WE-type alloy samples after non-static immersion in
Hank’s solution for 24 h. For ZK30 sample, after immer-
sion, slight shallow pitting damage was uniformly
distributed on the surface (Fig. 4a), and the pitting layer
appeared to be composed of small, agglomerated particles
(Fig. 4b). ZK60 sample showed a degradation pattern
similar to ZK30, but the pitting damage was much severer
than that on ZK30 sample (Fig. 4c, d). WE-type alloy
sample showed a different mode of degradation as com-
pared with ZK30 and ZK60 samples; pitting on the surface
was highly localized (Fig. 4e) and deep into the sample
bulk (Fig. 4f).
After a prolonged immersion period (7 days), the sur-
faces of all alloy samples were covered by a layer con-
taining small, white particles (Fig. 5). When the surface
morphologies of ZK30 (Fig. 5a, b) and WE-type alloy
(Fig. 5e, f) samples after 7-day immersion were compared,
it was found that more particles were formed on the WE-
type alloy sample surface. It is of interest to note that the
surface of ZK60 sample was completely different, being
porous and sponge-like (Fig. 5c). Observation at a higher
magniﬁcation showed that the surface was composed of
small, agglomerated particles (Fig. 5d).
To determine the elemental compositions of the particles
formed on ZK30 sample surface during the non-static
immersion testing, EDX analysis was performed, which
revealedthepresenceofCa,Mg,PandO(Fig. 6),suggesting
that these particles were mainly composed of magnesium,
calcium and phosphate. The Ca/P molar ratio of the surface
layer was lower than the ideal Ca/P molar ratio of
hydroxyapatite (1.67).Previous studies on other magnesium
Fig. 2 Surface macro-morphologies of a, b and c WE-type alloy, d and e ZK60 and f, g and h ZK30 samples after static immersion in Hank’s
solution for different periods of time. ZK60 sample was completely degraded after immersion for 12 weeks
Fig. 3 Hydrogen evolution of magnesium alloy samples as a function
of time during static immersion in Hank’s solution
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123alloys for biodegradable implants showed that the surface
layer was composed of magnesium calcium phosphate
(Mg–CP) or amorphous calcium phosphate particles [6, 30].
It is most likely that the Mg–CP compound was also formed
on the surface of ZK30 sample. In addition, it was noticed
that the elemental composition of the deposited particles
changed with immersion time. With increased soaking time,
the atomic content of Mg decreased, while the atomic con-
tents of Ca and P increased, as shown in Fig. 6.
To identify the phases formed on the surface of ZK30
sample after 7-day immersion, XRD analysis was carried
out and the results showed strong magnesium peaks and a
number of additional weak peaks (Fig. 7). The peaks
emerging from the surface of the tested sample corre-
sponded to magnesium-substitute calcium phosphate [31],
which was in agreement with the ﬁnding from the EDX
analysis.
3.3 Ion release during non-static immersion
The changes of ion concentrations and pH value of the
soaking medium over time during non-static immersion are
presented in Fig. 8. ICP-OES analysis showed that the
variations of ion concentrations in the immersion medium
for ZK30 were quite similar to those for the WE-type alloy.
A signiﬁcant increase in Mg
2? concentration (Fig. 8a) and
Fig. 4 SEM micrographs of a and b ZK30, c and d ZK60 and e and f WE-type alloy samples after non-static immersion in Hank’s solution for
24 h
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2? and PO4
3- concentrations (Fig. 8b, c)
were observed at the early stage of the immersion testing,
indicating rapid release of magnesium ions and consump-
tion of Ca
2? and PO4
3- ions. After 1-day immersion, the
Mg ion concentration tended to stabilize and the concen-
trations of Ca and P ions gradually changed toward those in
the initial Hank’s solution, as a result of refreshing 50% of
the solution and the formation of a surface layer that could
hinder further Mg ion release from the substrate, and Ca
and P ion deposition [30, 31]. Rapid degradation of ZK60
sample, relative to ZK30 and WE-type alloy samples,
resulted in a signiﬁcant increase in Mg
2? concentration and
decreases in Ca
2? and PO4
3- concentrations in the
immersion medium during the testing (Fig. 8a–c). After
1-day immersion and refreshing of 50% of the solution, the
ion concentrations became quite stable and deviated much
from the initial ion concentrations in Hank’s solution.
These results are in agreement with the degradation rate of
ZK60 in the static immersion tests; all the results point
towards ZK60 as the fastest degrading alloy. The results
from ICP-OES analysis suggested that, during the testing,
the Mg, Ca and P ion concentrations in the immersion
medium for ZK30 sample were within the tolerable ranges
for bone-related cells [7, 32, 33]. The Zn and Zr ion
Fig. 5 SEM micrographs of a and b ZK30, c and d ZK60 and e and f WE-type alloy samples after non-static immersion in Hank’s solution for
7 days
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0.0001 mmol/l, indicating limited release of these two
elements to the immersion medium.
The variation of the pH value of the immersion medium
with time was determined and the results are shown in
Fig. 8d. The pH value of the solution with ZK30 sample
increased from 7.30 to 8.31 during the ﬁrst 3 days.
Refreshing 50% of the solution did not seem to affect the
tendency. Thereafter, the pH value decreased slightly to
7.95 on day 5 and remained stable at the level of 8.0 during
the last 3 days. The trend of the pH change of the solution
with WE-type alloy sample was very similar to that with
ZK30 sample, although the pH values were all higher.
However, the pH value of the solution with ZK60 sample
changed in a different way; the pH value increased rapidly
to 10.31 during the ﬁrst day immersion and then gently
increased to 10.65 on day 7.
3.4 Cytotoxicity of ZK30 in comparison with
the WE-type alloy and HA
Since ZK60 showed a rather high degradation rate that
was not desirable for biomedical applications, cytotoxic-
ity evaluation of ZK60 was not made. The results
obtained from ICP-OES analysis and pH measurements
suggested that the degradation eluates from the ZK30 and
WE-type alloy might not induce toxicity to bone-related
cells. To conﬁrm this hypothesis, cytotoxicity tests were
performed and biocompatible HA was used as reference.
It was found that, at the tested concentration of the
Fig. 6 EDX analysis of the
particles deposited on the
surfaces of ZK30 alloy samples
after non-static immersion in
Hank’s solution for a 24 h and
b 7 days
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cytocompatibilities quite similar to HA after 1-day
incubation (Fig. 9). After a prolonged incubation period
of 7 days, the rBMSC cell proliferation in the extract of
ZK30 sample was found to be signiﬁcantly higher than
that of HA sample (P\0.05) and slightly higher than
that of WE-type alloy sample.
4 Discussion
In recent years, extensive research on magnesium and its
alloys as potential biodegradable materials has been carried
out. However, only limited efforts have been made to study
the alloys with compositions pertaining to biomedical
applications. In the present research, the general long-term
degradation behavior of the WE-type alloy, ZK30 and
ZK60 alloys was evaluated by static immersion tests in
which the concentration of Cl
- ions was maintained at a
constant level. Such a static immersion system may not
exactly simulate the actual physiological conditions in the
human body, because the body ﬂuid circulates dynamically
and, moreover, ion concentrations differ in different parts
of the human body [21]. Nevertheless, since the local
concentration of Cl
- ions is one of the most important
factors that determines the degradation rate of magnesium
alloys when they are exposed to an aggressive electrolyte
such as simulated body ﬂuid or a NaCl solution [11], dif-
ferent behavior between different magnesium alloys in
degradation rate can be revealed, if testing parameters such
as ion concentrations in the immersion system are kept
unchanged.
For magnesium alloys to be used as viable implant
materials, their degradation rates should not exceed the
healing rate of the affected tissue. They should remain
present in the body and maintain their mechanical integrity
Fig. 7 XRD patterns of ZK30 samples a before and b after non-static
immersion in Hank’s solution for 7 days
Fig. 8 Variations of a Mg,
b Ca and c P ion concentrations
and d pH value of the medium
with time during non-static
immersion in Hank’s solution.
Zn and Zr iron concentrations
were below 0.0001 mmol/l and
therefore they are not presented
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123at least for a period of 12–18 weeks, while the bone tissue
heals itself [1, 6]. The results obtained from previous in
vivo studies have shown a moderate degradation rate of
WE43 [6]. The results from the present long-term static
immersion tests showed that the ZK30 alloy possessed a
higher corrosion resistance than the WE-type alloy. The
superior corrosion resistance of ZK30 may be attributed to
the beneﬁcial effects of certain amounts of Zn and Zr on
the corrosion resistance by overcoming the harmful cor-
rosive effect of impurities and leading to ﬁner grain sizes
[11, 15–17] and to the precipitation of phosphate that forms
a protective layer on the surface. By contrast, ZK60
showed a rather accelerated degradation rate; by the end of
week 12, the sample was degraded completely. Obviously,
the signiﬁcant difference between ZK30 and ZK60 in
degradation behavior is related to the higher content of zinc
in the latter leading to the formation of second-phase par-
ticles and micro-galvanic cells. It has been reported that,
the addition of zinc to magnesium is usually limited to
1–3%, if improvement in corrosion resistance is expected
[34, 35]. Within the range of 1–3%% Zn, an increase of Zn
content from 2 to 3% moves the corrosion potential to a
more negative value and thus reduces the corrosion resis-
tance [36]. When the Zn content in a magnesium alloy goes
beyond 3 wt%, a considerable amount of the Mg7Zn3 phase
will form in the magnesium matrix according to the Mg–Zn
binary phase diagram [12], and these second-phase parti-
cles will result in micro-galvanic coupling with the matrix,
thus accelerating the corrosion of the material [36]. The
results suggest that the degradation rate of Zn-containing
magnesium alloys produced by the conventional techniques
may be adjustable by ﬁne-tuning the Zn content to meet the
clinical needs of implant materials in degradation rate for
different applications.
It is worth mentioning that for wrought Mg–Zn–Zr
alloys produced through the conventional casting and
forming routes (i.e. those in the ASTM standards), the zinc
content is usually limited to the maximum solubility of
zinc in magnesium (6.2 wt% at 635C) so as to make alloy
responsive to the solution and aging treatment and to avoid
the formation of the Mg ? MgZn eutectic in the alloy. A
zinc content closer to this maximum solubility leads to
more MgZn precipitates at room temperature under the
equilibrium condition and thus to higher mechanical
strength but lower corrosion resistance. However, when
rapid solidiﬁcation techniques are employed, such as melt
spinning or copper-mould casting, the Zn content can be
extended far beyond the maximum solubility of 6.2 wt%
under the equilibrium condition. Within the glass-forming
composition range of 21–35 at.% zinc, corresponding to
42–59 wt% zinc, the amorphous structure of the parent
liquid can be retained in the rods with a diameter of 1 mm
or larger [37]. When the zinc content is over 28 at.% (or
51 wt%), a dense amorphous layer rich in Zn (instead of
Mg) and oxygen is formed to protect the surface, slow
down degradation rate and reduce hydrogen evolution per
unit time [37, 38]. This concerns a different, yet very
interesting strategy in alloy design and material fabrication
for biodegradable magnesium alloys.
The degradation of magnesium alloys inevitably leads to
the evolution of hydrogen. Hydrogen evolving from a
degrading magnesium implant can be accumulated in gas
pockets next to the implant, which will delay the healing of
the surgery region and lead to necrosis of tissues, because
the gas pockets can cause tissues and tissue layers to sep-
arate [39]. Therefore, it is of vital importance to limit the
hydrogen evolution from magnesium implant to a mini-
mum level. Obviously, the most efﬁcient and direct way to
lowering the hydrogen evolution is to improve the corro-
sion resistance of the magnesium alloy. Compared with the
WE-type alloy, ZK30 had noticeably less release of
hydrogen over the ﬁrst 17 weeks and a negligibly low level
of hydrogen evolution was retained over a period from the
17th week to the 21st week. This is attributed to the
superior corrosion resistance of the alloy, because every
dissolved mole of magnesium produces 1 mol of hydrogen
[11].
Mg s ðÞþ2H2O ! Mg OH ðÞ 2 s ðÞþH2 g ðÞ ð 1Þ
In a previous in vivo study, hydrogen evolving from WE43
during degradation was considered tolerable and could be
dispersed by surrounding tissues [6]. It is therefore rea-
sonable to expect that the hydrogen evolution from ZK30
during degradation should be a matter of less concern after
Fig. 9 Rabbit marrow stromal cell viability expressed by the optical
density of the cells measured with enzyme-linked immunoadsorbent
assay after one and 7 days of culture in ZK30, WE-type alloy and HA
extraction media. The asterisk (*) indicates that the cell proliferation
in the ZK30 alloy extract was signiﬁcantly different from that of the
HA extract (P\0.05)
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123implantation, because the amount of hydrogen release from
ZK30 is less than that from the WE-type alloy.
The surface characteristics of magnesium alloys relevant
to biomedical applications, such as surface layer deposi-
tion, ion release and alkanization caused by in vivo cor-
rosion, are another concern in selecting these alloys as
biodegradable materials. The results obtained from SEM,
EDX and XRD analyses conﬁrmed that the main com-
pound of the surface layer on ZK30 sample was Mg
2?
substituted calcium phosphate, which was formed by the
dissolution of magnesium and simultaneously deposition of
calcium phosphate from Hank’s solution. Such a layer is
believed to bring additional beneﬁts to the material at the
early stage after implantation, since it has shown improved
biocompatibility and osteoconductivity in comparison with
calcium phosphate and hydroxyapatite [40, 41]. It was
reported that magnesium alloys could bond with sur-
rounding tissue by the formation of a Mg-substituted cal-
cium phosphate layer on the surface. Osteoconductive
bioactivity of magnesium-based metals was suggested,
based on the observed increase in bone apposition around
magnesium-based implants as compared to polylactic acid
(PLA) [6]. It should however be noted that the surface layer
formed on magnesium alloys is not as dense and homo-
geneous as a layer formed by applying coating for the
improvement of corrosion resistance [42]. Therefore, the
alloying elements and their amounts are the important
factors that contribute to the enhanced corrosion resistance
of ZK30. It is reasonable to expect that ZK30, being able to
promote the precipitation of a magnesium-substituted cal-
cium phosphate layer, will possess enhanced osteocon-
ductivity as WE43 does [6].
It should be kept in mind that, even though the surface
layer formed on ZK30 sample is expected to be biocom-
patible and osteoconductive as that formed on the surface
of other magnesium alloys, it is necessary to determine the
ion release and pH values during non-static immersion,
because the release of metallic ions and alkanization during
the corrosion of Mg-based alloys may indicate cytotoxicity
to surrounding tissues. Therefore, the ion concentrations of
Mg and alloying elements in the immersion media for
ZK30 and WE-type alloy samples were determined. The
results conﬁrmed that the Mg, Zn and Zr ion concentrations
in the non-static immersion medium for ZK30 throughout
the testing period of 7 days were all below tolerable levels
for bone-related cells [43, 44]. The consumption of Ca
2?
and PO4
3- ions was attributed to the deposition of mag-
nesium calcium phosphate on sample surface, which is
important for the formation of bonding between material
and bone tissue. As far as the pH variation is concerned, it
is known that cells are highly sensitive to environment
ﬂuctuations, and a signiﬁcant increase in pH value can
cause fatal effects on the viability of cell and serious
hemolysis. The results of the present research indicate that
the degradation of ZK30 caused more moderate changes in
pH value (around 8.0) than that of the WE-type alloy, and
the pH values ﬂuctuating slightly over time fell into the
tolerable range of pH values for most human cells (6.0–9.0)
[45]. One may therefore expect that the degradation pro-
cess of the ZK30 alloy will not cause signiﬁcant environ-
ment ﬂuctuations that may be fatal for cells and the alloy
will possess a cytocompatibility similar to or better than the
WE43 alloy. To conﬁrm this hypothesis, a preliminary in
vitro cell-material interaction analysis based on the extracts
formed by the degradation of samples in a cell culture
medium was performed. As compared to HA, both the
ZK30 and WE-type alloy did not show signiﬁcant cyto-
toxicity against the rBMSC cells in the tested concentration
of the extract. Considering the fact that HA with a chemical
composition similar to that of the natural bone is biocom-
patible with the hard tissue of the human being, it is rea-
sonable to envisage that the ZK30 alloy is cytocompatible
to the surrounding tissues after implantation. Moreover, it
was observed that, after 7-day incubation, the ionic prod-
ucts of ZK30 dissolution could provide a better stimulus
for cell proliferation than those of HA and the WE-type
alloy (P\0.05). The enhanced cell proliferation could be
attributed to the moderate Mg ion release from ZK30,
which may have a beneﬁcial effect on some structures
including those of the cells in the relevant local tissue, in
addition to the favorable characteristics including the var-
iation of pH value in the immersion solution with time and
surface magnesium calcium phosphate deposition [46].
Zreiqat et al. [47] reported that magnesium ion modiﬁed
bioceramic substrata could enhance the human bone-
derived cell (HBDC), and due to functional roles and
presence in bone tissue, magnesium may actually have
stimulatory effects on the growth of new bone tissue [1,
48]. It may thus be inferred that the enhancement in cell
proliferation in the presence of the ZK30 magnesium alloy
may result in enhanced bone healing in vivo. However,
further in vitro cell-culture tests and the characterization of
in vitro degradation behavior of the material in the pres-
ence of bone cells are necessary. In addition, in vivo
studies will be needed to validate and supplement the in
vitro results. Encouraging in vivo results of ZK30 are
expected. This expectation is based on the positive results
of the in vivo tests of the single-phase binary Mg–6Zn
alloy without MgZn precipitates after a solid solution
treatment and extrusion [49], being similar to the present
ZK30 alloy in terms of phase constitution. The in vivo tests
of this binary Mg–6Zn alloy indicated (i) a relatively high
degradation rate of the alloy after 14 weeks of implantation
(2.32 mm/year) in comparison with other magnesium
alloys, (ii) different surface morphologies and composi-
tions between in vitro and in vivo, (iii) formation of
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123trabeculae and osteoblasts despite a gap between the
implant and surrounding bone tissues due to rapid degra-
dation, and (iv) good biocompatibility as evidenced by no
negative effect of zinc release on the heart, kidney, liver
and spleen [49]. In addition, the same binary alloy Mg–6Zn
without the speciﬁc heat treatment, presumably containing
MgZn precipitates, subjected to animal tests for 14 weeks,
also showed no effect on the chromatics, structure or
function of heart, liver, kidney or spleen after implantation
for 6 weeks [50].
5 Conclusions
In the present in vitro study, magnesium alloys with zinc
and zirconium as the alloying elements (ZK30 and ZK60)
were investigated with respect to (i) their degradation rate
and hydrogen evolution during static immersion, (ii) ion
release and the surface layer formed during non-static
immersion and (iii) cytocompatibility with the rBMSC
cells in order to exploit their potential as biodegradable
materials. Comparison was made with a WE-type magne-
sium alloy. Among these three magnesium alloys, the
ZK30 alloy showed the lowest degradation rate and the
least hydrogen evolution during static immersion over a
period of 21 weeks. It is likely that the degradation rate of
Mg–Zn–Zr alloys can be adjusted by modifying the Zn
content in the alloy. Furthermore, ZK30 showed moderate
ion release, surface alkanization and, more importantly,
good cytocompatiblily with a potential stimulatory effect
on bone-related cells. The results obtained from these
investigations suggested that Zn- and Zr-containing mag-
nesium alloys, especially ZK30, could hold promise as
candidate materials with adjustable degradation rate for
orthopedic applications.
Acknowledgements The authors would like to thank Prof. Jiang
Chang and Dr. Wanyin Zhai of the Biomaterials and Tissue Engi-
neering Research Center, Shanghai Institute of Ceramics, Chinese
Academy of Sciences, China, for the preparation of hydroxyapatite
disks, assistance in the cytotoxicity tests and fruitful discussions.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Staiger MP, Pietak AM, Huadmai J, Dias G. Magnesium and its
alloy as orthopaedic biomaterials: a review. Biomater.
2006;27:1728–34.
2. Wintermantel EHS. Medizintechnik mit Biokompatiblen Wer-
kstoffen und Verfahren. 3rd ed. Berlin, Heldelberg, New York:
Springer; 2002.
3. Song G. Control of biodegradation of biocompatible magnesium
alloys. Corros Sci. 2007;49:1696–701.
4. Witte F, Hort N, Vogt C, Cohen S, Kainer KU, Willumeit R,
Feyerabend F. Degradable biomaterials based on magnesium
corrosion. Curr Opin Solid State Mater Sci. 2008;12:63–72.
5. El-Rahman SSA. Neuropathology of aluminium toxicity in rats
(Glutamate and GABA impairment). Pharmacol Res. 2003;
47:189–94.
6. Witte F, Kaese V, Haferkamp H, Switzer E, Meyer-Lindenberg
A. In vivo corrosion of four magnesium alloys and the associated
bone response. Biomater. 2005;24:4913–20.
7. Gu X, Zheng Y, Cheng Y, Zhong S, Xi T. In vitro corrosion and
biocompatibility of binary magnesium alloys. Biomater. 2009;
30:484–98.
8. Schranz D, Zartner P, Michel-Behnke I, Akinturk H. Bioresorb-
able metal stents for percutaneous treatment of critical recoarc-
tation of the aorta in a newborn. Catheter Cardiovasc Interv.
2006;67:671–3.
9. Ahmed T, Rack HJ. Low modulus biocompatible titanium base
alloys for medical devices. US Patent, No. 5871595.
10. Boehlert CJ, Knittel K. The microstructure, tensile properties, and
creep behaviour of Mg–Zn alloys containing 0–4.4 wt% Zn.
Mater Sci Eng A. 2006;417:315–21.
11. Song G, Atrens A. Corrosion mechanisms of magnesium alloys.
Adv Eng Mater. 1999;1:11–33.
12. Friedrich HE, Mordike BL. Magnesium technology. Berlin,
Heidelburg: Springer-Verlag; 2006.
13. Gao JC, Wu S, Qiao LY, Wang Y. Corrosion behavior of Mg and
Mg-Zn alloys in simulated body ﬂuid. Trans Nonferrous Met Soc
China. 2008;18:588–92.
14. Seiler H. Metal ions in biological system. In: Concepts on metal
ion toxicity. vol. 20. Marcel Dekker, Inc. 1986.
15. Babkin VM. Effect of zirconium on the grain size of magnesium
containing 4.5% Zn. Met Sci Heat Treat. 2004;5:543–4.
16. Song G, St John D. The effect of zirconium grain reﬁnement on
the corrosion behavior of magnesium-rare earth alloy MEZ. J
Light Met. 2002;1:1–16.
17. Song G. Recent progress in corrosion and protection of magne-
sium alloys. Adv Eng Mater. 2005;7:563–86.
18. Saldana L, Mendez-Vilas A, Jiang L, Multigner M, Conzalez-
Carrasco JL, Perez-Prado MT. In vitro biocompatibility of an
ultraﬁne grained zirconium. Biomater. 2007;28:4343–54.
19. Kulakov OB, Doktorov AA, D’iakova SV, Denisov-Nikol’skii I,
Grotz KA. Experimental study of osseointegration of zirconium
and titanium dental implants. Morfologiia. 2005;127:52–5.
20. Loos A, Rohde R, Haverich A, Barlach S. In vitro and in vivo
biocompatibility testing of absorbable metal stents. Macromol
Symp. 2007;253:103–8.
21. Levesque J, Hermawan H, Dube D, Mantovani D. Design of a
pseudo-physiological test bench speciﬁc to the development of
biodegradable metallic biomaterials. Acta Biomater. 2008;4:284–
95.
22. Marc B, Lemaitre J. Can bioactivity be tested in vitro with SBF
solution? Biomaterials. 2009;30:2175–9.
23. Yamamoto A, Hiromoto S. Effect of inorganic salts, amino acids
and proteins on the degradation of pure magnesium in vitro.
Mater Sci Eng C. 2009;29:1559–68.
24. Kokubo T. Surface chemistry of bioactive glass-ceramics. J Non-
Cryst Solids. 1990;120:138–51.
25. Mauney JR, Jaquiery C, Volloch V, Heberer M, Martin I, Kaplan
DL. In vitro and in vivo evaluation of differentially demineralized
cancellous bone scaffolds combined with human bone marrow
stromal cells for tissue engineering. Biomater. 2005;26:3173–85.
26. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous
soluble tetrazolium/formazan assay for cell growth assays in
culture. Cancer Commun. 1991;3:207–12.
2634 J Mater Sci: Mater Med (2010) 21:2623–2635
12327. Li Z, Gu X, Lou S, Zheng Y. The development of binary Mg-Ca
alloys for use as biodegradable materials within bone. Biomater.
2008;29:1329–44.
28. Jarcho M. Calcium phosphate ceramics as hard tissue prosthetics.
Clin Orthop Relat Res. 1981;157:259–78.
29. Neo M, Kotani S, Nakamura T, Yamamuro T, Ohtsuki C, Kokubo
T, Bando Y. A comparative study of ultra structure of the
interfaces between four kinds of surface-active ceramics and
bone. J Biomed Mater Res. 1992;26:1419–32.
30. Xu L, Zhang E, Yin D, Zeng S, Yang K. In vitro corrosion
behavior of Mg alloys in a phosphate buffered solution for bone
implant application. J Mater Sci Mater Med. 2008;19:1017–25.
31. Yang L, Zhang E. Biocorrosion behavior of magnesium alloy in
different simulated ﬂuids for biomedical application. Mater Sci
Eng C. 2009;29:1691–6.
32. Romani A, Scarpa A. Regulation of cell magnesium. Arch Bio-
chem Biophys. 1992;298:1–12.
33. Ilich JZ, Kerstetter JE. Nutrition in bone health revisited: a story
beyond calcium. J Am Coll Nutr. 2000;19:715–37.
34. Bhan S, Lal A. The Mg–Zn–Zr system. J Phase Equil. 1993;
14:634–7.
35. Froats A, Aune TK, Hawke D, Unsworth W, Hillis J. ASM
handbook: corrosion. vol. 1, 39 edn. ASM Inter. 1987; p. 740–54.
36. Zhang E, Yin D, Xu L, Yang L, Yang K. Microstructure,
mechanical and corrosion properties and biocompatibility of Mg-
Zn-Mn alloys for biomedical application. Mat Sci Eng C.
2009;29:987–93.
37. Ma E, Xu J. Biodegradable alloys: the glass window of oppor-
tunities. Nat Mater. 2009;8:855–7.
38. Zberg B, Uggowitzer PJ, Lo ¨fﬂer J. ZMgZnCa glasses without
clinically observable hydrogen evolution for biodegradable
implants. Nat Mater. 2009;8:887–91.
39. Mcbride ED. Absorbable metal in bone surgery. J Am Med
Assoc. 1938;111:2464–7.
40. Qi G, Zhang S, Khor KA, Lye SW, Zeng X, Weng W, Liu C,
Venkatraman SS,Ma L.Osteoblastic cellresponseonmagnesium-
incorporated apatite coatings. Appl Surf Sci. 2008;255:304–7.
41. Sader M, LeGeros R, Soares G. Human osteoblasts adhesion and
proliferation on magnesium-substituted tricalcium phosphate
dense tablets. J Mater Sci Mater Med. 2009;20:521–7.
42. Retting R, Virtanen S. Composition of corrosion layers on a
magnesium rare-earth alloy in simulated body ﬂuids. J Biomed
Mater Res A. 2009;88A:359–69.
43. Hallab NJ, Vermes C, Messina C, Roebuck KA, Glant TT, Jocobs
JJ. Concentration- and composition-dependent effects of metal
ions on human MG-63 osteoblasts. J Biomed Mater Res.
2002;60:420–33.
44. Schmalz G, Langer H, Schweikl H. Cytotoxicity of dental alloy
extracts and corresponding metal salt solution. J Dent Res.
1998;77:1772–8.
45. Harrison MA, Rae IF. General techniques of cell culture. Cam-
bridge: Cambridge University Press; 1997. p. 7–31.
46. William D. New interests in magnesium. Med Dev Tech.
2006;17:9–10.
47. Zreiqat H, Howlett CR, Zannettino A, Evans P, Schulze-Tanzil
G, Kanbe C. Mechanisms of magnesium-stimulated adhesion of
osteoblastic cells to commonly used orthopedic implants. J Bio-
med Mater Res. 2002;62:175–84.
48. Yamasaki Y, Yoshida Y, Okazaki M, Shimazu A, Kubo T,
Akagawa Y, Uchida T. Action of FGMgCO3Ap-collagen com-
posite in promoting bone formation. Biomater. 2003;24:4913–20.
49. Zhang S, Zhang X, Zhao C, Li J, Song Y, Xie C, Tao H, Zhang Y,
He Y, Jiang Y, Bian Y. Research on an Mg-Zn alloy as a
degradable biomaterial. Acta Biomater. 2010;6:626–40.
50. He YH, Tao HR, Zhang Y, Jiang Y, Zhang SX, Zhao CL, Li JN,
Zhang BL, Song Y, Zhang XN. Biocompatibility of bio-Mg–Zn
alloy within bone with heart, liver, kidney and spleen. Chin Sci
Bull. 2009;54:481–91.
J Mater Sci: Mater Med (2010) 21:2623–2635 2635
123